| Case Name | Drug | Patent No(s). | Publicly Available Terms |
|---|---|---|---|
| Novartis Pharms. Corp. v. Amneal Pharms. LLC, 15-1025 (D. Del.) | Exelon® Patch (rivastigmine transdermal system) |
6,316,023
6,335,031
|
N/A. |
| AstraZeneca AB v. Micro Labs USA, Inc., 15-3376, 15-7921 (D.N.J.) | Daliresp® (roflumilast tablets) |
5,712,298
8,431,154
8,604,064
8,618,142
8,536,206
|
N/A |
| Warner Chilcott (US), LLC v. Zydus Pharms. (USA), Inc., 16-0323 (E.D. Tex.) | Delzicol® (mesalamine delayed-release capsules) |
6,649,180
|
Zydus and Cadila may market a generic version of Delzicol in the US starting on March 1, 2020, pending FDA approval, or earlier under certain circumstances. |
Related Attorneys
Counsel
